Skip to main content
SSY Group Limited logo

SSY Group Limited — Investor Relations & Filings

Ticker · 2005 ISIN · KYG8406X1034 HKEX Manufacturing
Open in API
Filings indexed 1,213 across all filing types
Latest filing 2023-03-28 Notice of Dividend Amou…
Country HK Hong Kong
Listing HKEX 2005

About SSY Group Limited

http://www.ssygroup.com.hk

SSY Group Limited is an investment holding company specializing in the research, development, manufacturing, and sale of pharmaceutical products. The Group is a prominent manufacturer, with a core focus on producing a wide range of intravenous infusion solutions and finished drugs. Complementing its pharmaceutical offerings, the company also manufactures essential packaging materials, including non-PVC soft bags and PP plastic containers. SSY Group supplies its comprehensive product line, which often utilizes green production technologies aimed at reducing costs and power consumption, primarily to hospitals and medical institutions.

Recent filings

Filing Released Lang Actions
Final Dividend for the year ended 31 December 2022
Notice of Dividend Amount Classification · 100% confidence The document is titled 'Cash Dividend Announcement for Equity Issuer' and provides detailed information about a final dividend for the year ended 31 December 2022, including dividend amount, payment date, record date, ex-dividend date, and shareholder approval date. It does not contain financial statements or comprehensive financial data but focuses solely on dividend details. The document length is 4012 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of a Notice of Dividend Amount (DIV).
2023-03-28 English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2022
Annual Report Classification · 95% confidence The document is an announcement titled 'ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2022' from SSY Group Limited. It contains detailed financial performance data for the full fiscal year 2022, including revenue, profit, dividend distribution, business review, product sales breakdown, and research and development activities. The content is comprehensive and covers the entire year's financial results and operational highlights, which is characteristic of an Annual Report or Earnings Release. However, the length (15,000 characters) and the detailed financial and business analysis indicate it is more than a brief earnings release. The document is not merely an announcement of a report but contains substantive financial data and management commentary. Therefore, it fits best as an Annual Report (10-K equivalent) or a full Annual Results Announcement. Given the Hong Kong context and the detailed annual financial and operational review, the classification aligns with Annual Report (10-K). FY 2022
2023-03-28 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 90% confidence The document is a voluntary announcement by the board of directors regarding the approval of a drug product by a regulatory authority. It is an update on product development and does not contain financial data, detailed financial performance, or regulatory certifications. The document is short (1665 characters) and serves to inform shareholders and investors about business developments rather than reporting financial results or governance changes. It is not an annual report, interim report, earnings release, or any other detailed financial or governance filing. It is also not a regulatory filing or certification. The content fits best under a general regulatory announcement category, but since it is a voluntary business update, it does not fit neatly into the defined categories like CAP (capital/financing update) or MANG (management changes). Given the options, the best fit is Regulatory Filings (RNS) as a fallback for miscellaneous announcements that do not fit other categories.
2023-03-27 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON BUSINESS DEVELOPMENT
Regulatory Filings Classification · 85% confidence The document is a voluntary announcement by the board of directors regarding a business development update, specifically the selection of a subsidiary into a government-recognized List of Green Factory. It is a short announcement (1819 characters) and does not contain financial statements, detailed financial data, or regulatory filings. It is not an annual or interim report, audit report, or earnings release. It is not a regulatory filing or certification. The content focuses on business development and environmental recognition, which aligns with an Environmental & Social Information (ESG) update. However, the document is brief and primarily an announcement rather than a detailed ESG report. Given the nature and length, it fits best under Regulatory Filings (RNS) as a general announcement that does not fit other categories specifically. The document is not a report publication announcement since it does not mention any report being published or attached.
2023-03-24 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement from the board of directors about an update on product development, specifically the approval for drug production and registration. It is a short announcement (1650 characters) and does not contain financial data, regulatory filings, or detailed reports. It is not an annual report, earnings release, or any detailed financial or governance report. It is an update on business development made to inform shareholders and investors. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2023-03-24 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON PRODUCT DEVELOPMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors regarding the approval and launch of a new pharmaceutical product. It is an update on product development rather than a financial report, regulatory filing, or meeting-related document. The length is short (1853 characters), and it does not contain financial data, voting results, or management changes. It is not an announcement of a report publication but a business update. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous company update, which corresponds to Regulatory Filings (RNS).
2023-03-23 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.